New tetanus antibody could replace Blood-Derived treatments
NCT ID NCT06939777
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1/2 trial tested a new lab-made antibody called SNA02-48 for treating tetanus in 255 Chinese adults. The study compared SNA02-48 to the standard treatment (human tetanus immunoglobulin) to see if it is safe and how well it works. The goal is to find a more reliable and potentially safer option for preventing tetanus infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SNA02-48 (a lab-made antibody against tetanus toxin)
What this could lead to
If successful, this could offer a new, safer alternative to current tetanus treatments derived from human blood.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 255 participants, so results may not confirm effectiveness or safety in larger populations. The antibody may not work as well as existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Hospital of Anhui Medical Universiy
Hefei, Anhui, 230601, China